Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

152 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical review 165: Markers of bone remodeling in metastatic bone disease.
Fohr B, Dunstan CR, Seibel MJ. Fohr B, et al. Among authors: dunstan cr. J Clin Endocrinol Metab. 2003 Nov;88(11):5059-75. doi: 10.1210/jc.2003-030910. J Clin Endocrinol Metab. 2003. PMID: 14602728 Review.
Quantitative bone histology in the hypercalcemia of malignant disease.
McDonnell GD, Dunstan CR, Evans RA, Carter JN, Hills E, Wong SY, McNeil DR. McDonnell GD, et al. Among authors: dunstan cr. J Clin Endocrinol Metab. 1982 Dec;55(6):1066-72. doi: 10.1210/jcem-55-6-1066. J Clin Endocrinol Metab. 1982. PMID: 7130337
The bone remodeling environment is a factor in breast cancer bone metastasis.
Ooi LL, Zheng Y, Stalgis-Bilinski K, Dunstan CR. Ooi LL, et al. Among authors: dunstan cr. Bone. 2011 Jan;48(1):66-70. doi: 10.1016/j.bone.2010.05.007. Epub 2010 May 21. Bone. 2011. PMID: 20472107 Review.
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
Dunstan CR, Felsenberg D, Seibel MJ. Dunstan CR, et al. Nat Clin Pract Oncol. 2007 Jan;4(1):42-55. doi: 10.1038/ncponc0688. Nat Clin Pract Oncol. 2007. PMID: 17183355 Review.
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ. Morony S, et al. Among authors: dunstan cr. Endocrinology. 2005 Aug;146(8):3235-43. doi: 10.1210/en.2004-1583. Epub 2005 Apr 21. Endocrinology. 2005. PMID: 15845617
Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men.
Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Khosla S, et al. Among authors: dunstan cr. J Clin Endocrinol Metab. 2002 Apr;87(4):1550-4. doi: 10.1210/jcem.87.4.8397. J Clin Endocrinol Metab. 2002. PMID: 11932280 Clinical Trial.
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR. Yoneda T, et al. Among authors: dunstan c. J Clin Invest. 1997 May 15;99(10):2509-17. doi: 10.1172/JCI119435. J Clin Invest. 1997. PMID: 9153295 Free PMC article.
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.
Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. Kostenuik PJ, et al. Among authors: dunstan cr. Endocrinology. 2001 Oct;142(10):4295-304. doi: 10.1210/endo.142.10.8437. Endocrinology. 2001. PMID: 11564687
Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone.
Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, Dunstan CR. Zheng Y, et al. Among authors: dunstan cr. Cancer Res. 2007 Oct 1;67(19):9542-8. doi: 10.1158/0008-5472.CAN-07-1046. Cancer Res. 2007. PMID: 17909065
Model structure and control of bone remodeling: a theoretical study.
Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, Mundy GR. Pivonka P, et al. Among authors: dunstan cr. Bone. 2008 Aug;43(2):249-63. doi: 10.1016/j.bone.2008.03.025. Epub 2008 Apr 15. Bone. 2008. PMID: 18514606
152 results
Jump to page